Abstract
Since intensive metabolic control and vigorous antihypertensive therapy only postpone, but do not prevent, end-stage renal failure (ESRF) in diabetics and because diabetics in many parts of the world are no longer excluded from ESRF programs, it is not surprising that a great and still increasing number of candidates for dialysis therapy and kidney transplantation consist of diabetic patients. At the moment 10%–25% of the population admitted to ESRF programs in the United States and Western Europe suffer from diabetes mellitus. Consequently, profound insight into the pathophysiology of glucose homeostasis and insulin kinetics in this complicated clinical condition is necessary to assure optimal therapy in nondialyzed, dialyzed, and recently kidney-transplanted diabetic patients. A perfect glycemic and metabolic control is obviously still the goal of therapy in these diabetics in order to reduce further morbidity in a group of patients already heavily burdened by severe complications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
DeFronzo RA, Tobin JD, Rowe J W, Andres R: Glucose intolerance in uremia: quantification of pancreatis beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 62: 425–435, 1978.
DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J: Insulin resistance in uremia. J Clin Invest 67: 563–568, 1981.
Smith D, DeFronzo RA: Insulin resistance in uremia mediated by postbinding defects. Kidney Int 22: 54–62, 1982.
Schmitz O, Alberti KGMM, Christensen NJ, Hasling C, Hjollund E, Beck-Nielsen H, Orskov H: Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. Metabolism 34: 465–473, 1985.
Schmitz O, Arnfred J, Orskov C, Nielsen OH: Uremia is characterized by impaired glucose-mediated glucose uptake and inappropriate hepatic glucose output to a.hyperglycemic challenge. (Submitted for publication), 1987.
McCaleb ML, Mevorach R, Freeman RB, Izzo MS, Lockwood DH: Induction of insulin resistance in normal adipose tissue by uremic human serum. Kidney Int 25: 416–421, 1984.
Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE: Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 28: 70–75, 1985.
Pedersen O, Schmitz O, Hjollund E, Richelsen B, Hansen HE: Postbinding defects of insulin action in human adipocytes from patients with uremia. Kidney Int 27: 780–784, 1985.
Pedersen O, Bech-Nielsen H: Insulin resistance and type 1 (insulin-dependent) diabetes mellitus. Diabetes Care 10: 516–523, 1987.
Schmitz O: Insulin-mediated glucose uptake in non-dialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 34: 1152–1159, 1985.
Schmitz O, Alberti KGMM, Orskov H: Insulin resistance in uraemic insulin-dependent diabetics: effect of dialysis therapy as assessed by the artificial endocrine pancreas. Acta Endocrinol (Copenh) 105: 371–378, 1984.
Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 27: 351–357, 1984.
Mondon CE, Dolkas CB, Reaven GM: Effect of acute uremia in insulin renewal by the isolated perfused rat liver and muscle. Metabolism 27: 133–142, 1978.
Rabkin R, Unterhalter SA, Duckworth WC: Effect of prolonged uremia on insulin metabolism by isolated liver and muscle. Kidney Int 16: 433–439, 1979.
Ferrannini E, Pilo A, Navalesi R, Citti L, Cecchetti P, Masoni A: Insulin kinetics and glucose-induced insulin delivery in chronically dialyzed subjects: acute effects of dialysis. J Clin Endicrinol Metab 49: 15–22, 1979.
Schmitz O, Hjollund E, Alberti KGMM, Orskov H, Beck-Nielsen H: Assessment of tissue sensitivity to insulin in uraemic patients on long-term haemodialysis therapy. Diabetes Res 2: 57–63, 1985.
Avram MM, Paik SK, Okanya D, Rajpal K: The natural history of diabetic nephropathy: unpredictable insulin requirements-a further clue. Clin Nephrol 21: 36–38, 1984.
Urion D, Vreman HJ, Winer MW: Effect of acetate on hypoglycemic seizures in mice. Diabetes 28: 1022–1026, 1979.
Schmitz O, Hansen AP, Hansen HE, Orskov H: Inhibition of arginine-and hypoglycemia-induced growth hormone release by acetate in dialyzed patients. Clin Nephrol 17: 70–76, 1982.
Hansen AaP, Orskov H, Hansen HE, Schmitz O, Posborg V, Nosadini GA, Noy GA, Alberti KGMM: Glucose control during hemodialysis of diabetic patients. J Artif Organs ISuppl] 5: 681–685, 1981.
Schade DS, Eaton RP, Spencer W, Goldman R, Corbett WT: The peritoneal absorption of insulin of diabetic man: a potential site for a mechanical insulin delivery system. Metabolism 28: 195–197, 1979.
Schade DS, Eaton RP, Friedman NM, Spencer WJ: Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia 19:35,-39, 1980.
Shapiro DJ, Blumenkrantz MJ, Levin SR, Coburn J W: Absorption and action of insulin added to peritoneal dialysate in dogs. Nephron 23: 174–180, 1979.
Janle-Swain E, Thornhill JA, Carter JM, Hinsman I, Jackson H, Swain SL, Ash SR: Improvement in kidney function with continuous intraperitoneal insulin infusion (CIPII) in severe diabetic glomerulopathy. Diabetic Nephropathy 2: 16–22, 1983.
Stephen RL, Maxwell JG, Kablitz C, Jacobsen SC, Hanover B, Tyler F: Intraperitoneal insulin regimens and diabetic nephropathy. In: Davison AM, Guillou PJ (eds) Proceedings of the European Dialysis and Transplant Association-European Renal Association, vol 20. London: Pitman, 1983, pp 692–699.
Johnson CA, Amidon G, Reichert JE, Porter WR: Absorption of insulin to the surface of peritoneal dialysis solution containers. Am J Kidnery Dis 3: 224–228, 1983.
Wideröe T-E, Smeby LC, Berg KJ, Jörstad S, Svartâs TM: intraperitoneal (1251) insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 23: 22–28, 1983.
Rottembourg J, Issad B, Poignet JL, Strippoli P, Balducci A, Slama G, Gahl GM: Residual renal function and control of blood glucose levels in insulin-dependent diabetic patients treated by CAPD. In: Keen H, Legrain M (eds) Prevention and treatment of diabetic nephropathy. Lancaster UK: MTP Press, 1983, pp 339–352.
Schmitz O, Sorensen SS, Alberti KGMM, Orskov H, Hansen HE: Metabolic control in newly kidney transplanted type 1 diabetics: ‘normalization’ by insulin pump treatment (CSII). J Diabetic Complications (in press), 1987.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Schmitz, O. (1988). Aspects of Insulin Treatment in Uremic Insulin-Dependent Diabetic Patients before and after Active Replacement Therapy. In: Mogensen, C.E. (eds) The Kidney and Hypertension in Diabetes Mellitus. Topics in Renal Medicine, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1974-1_44
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1974-1_44
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1976-5
Online ISBN: 978-1-4757-1974-1
eBook Packages: Springer Book Archive